Island Pharmaceuticals Limited

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Their main asset – ISLA-101 - was initially developed by their wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.